Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Hospital of Lithuanian University of Health Sciences Kaunas Clinics · Sağlık Bilimleri Üniversitesi · +10 more institutions
Abstract
Background: Biologic therapies are widely used in patients with ulcerative colitis. Head-to-head trials of these therapies in patients with inflammatory bowel disease are lacking. \n \nMethods: In a phase 3b, double-blind, double-dummy, randomized trial conducted at 245 centers in 34 countries, we compared vedolizumab with adalimumab in adults with moderately to severely active ulcerative colitis to determine whether vedolizumab was superior. Previous exposure to a tumor necrosis factor inhibitor other than adalimumab was allowed in up to 25% of patients. The patients were assigned to receive infusions of 300 mg of vedolizumab on day 1 and at weeks 2, 6, 14, 22, 30, 38, and 46 (plus injections of…
Citation impact
- FWCI
- 64.77
- Percentile
- 100%
- References
- 19
Authors
13- BEBruce E. SandsCorresponding
Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Sağlık Bilimleri Üniversitesi, Icahn School of Medicine at Mount Sinai
- LPLaurent Peyrin‐Biroulet
Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Centre Hospitalier Régional et Universitaire de Nancy, Sağlık Bilimleri Üniversitesi
- EVEdward V. Loftus
Mayo Clinic, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Sağlık Bilimleri Üniversitesi
- SDSilvio Danese
Humanitas University, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Sağlık Bilimleri Üniversitesi
- JCJean–Frédéric Colombel
Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Sağlık Bilimleri Üniversitesi, Takeda (United States), Icahn School of Medicine at Mount Sinai
Topics & keywords
- Vedolizumab
- Ulcerative colitis
- Medicine
- Adalimumab
- Internal medicine
- Inflammatory bowel disease
- Gastroenterology
- Dermatology
- Good health and well-being